Literature DB >> 11224097

Sertindole and several antipsychotic drugs differentially inhibit the discriminative stimulus effects of amphetamine, LSD and St 587 in rats.

J. Arnt1.   

Abstract

The effects of sertindole, clozapine, Cis(Z)-flupentixol and haloperidol on the discriminative stimulus properties of d-amphetamine (dopamine DA stimulant), d-LSD (5-HT(2) agonist) and St 587 (alpha(1)-adrenoceptor agonist; 2-chloro-5-trifluoromethyl-phenylimino)-imidazolidine) have been studied. Sertindole, a putative antipsychotic compound with limbic selectivity, antagonized the effects of d-LSD and St 587, whereas that of d-amphetamine was unchanged. Clozapine preferentially inhibited St 587, but also antagonized d-LSD and d-amphetamine, together with increases in reaction time. Cis(Z)-flupentixol antagonized d-amphetamine and St 587 effects, whereas haloperidol antagonized d-amphetamine only. Behavioural disruption was induced by haloperidol in St 587 and d-LSD-trained animals. The 5-HT(2) antagonist ketanserin selectively inhibited the effect of d-LSD, and the selective alpha(1)-adrenoceptor antagonist prazosin partially inhibited the effect of St 587, but did not inhibit d-LSD or d-amphetamine. The partial inhibition of St 587 effects by prazosin was not further increased by co-treatment with haloperidol. Prazosin partially substituted for the training dose of St 587. The results indicate that drug discrimination techniques can be used to demonstrate different activity profiles of typical and atypical neuroleptics. The classical neuroleptics have preferential amphetamine antagonistic activity, whereas clozapine has a broad activity profile. Furthermore, the atypical neuroleptic sertindole fails to induce acute DA antagonism in doses much higher than those inhibiting d-LSD and St 587.

Entities:  

Year:  1992        PMID: 11224097     DOI: 10.1097/00008877-199203010-00004

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  5 in total

1.  A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.

Authors:  D P van Kammen; J P McEvoy; S D Targum; D Kardatzke; T B Sebree
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP.

Authors:  Mirjana Carli; Eleonora Calcagno; Ester Mainini; Jorn Arnt; Roberto W Invernizzi
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

3.  Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system?

Authors:  J Arnt
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 4.  Sertindole : a review of its use in schizophrenia.

Authors:  David Murdoch; Gillian M Keating
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Lack of generalisation between the GABAA receptor agonist, gaboxadol, and allosteric modulators of the benzodiazepine binding site in the rat drug discrimination procedure.

Authors:  Signe Michelsen; Connie Sánchez; Bjarke Ebert
Journal:  Psychopharmacology (Berl)       Date:  2007-03-15       Impact factor: 4.415

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.